文献速递特殊人群用药抗菌药物管理抗栓抗凝管理

低体重患者的药物剂量设计要点

Drug dosing in patients with low body weight.
PubMed 文献 · Am J Health Syst Pharm · 2026-09-22

本文综述低体重患者药代动力学改变及剂量设计要点,指出相关研究主要限于抗菌药和抗凝药,标准剂量下药代与临床结局变异大,应将低体重视为特殊人群并个体化给药。

要点

  • 低体重患者用标准剂量可能导致药物浓度不当和不良反应。
  • 现有证据主要来自经肾清除的亲水性抗菌药和抗凝药。
  • 低体重应视为特殊人群,推荐个体化给药并加强研究。

核心结论

  • 低体重患者用药剂量信息匮乏,标准剂量下药代动力学和临床结局变异大,应视为特殊人群并寻求个体化给药。

研究设计与样本

  • 本文为综述,聚焦低体重患者剂量设计,指出现有研究主要限于抗菌药和抗凝药。

主要发现

  • 低体重患者使用正常体重标准剂量可能导致药物浓度不当和不良反应。
  • 现有低体重剂量研究主要限于抗菌药和抗凝药,多为经肾清除的亲水性药物。
  • 亲水性药物的分布容积和清除率结论可能不适用于亲脂性药物。
  • 亲脂性药物分布容积大且常经非肾途径清除,相关剂量信息很少。

临床怎么用

  • 低体重患者应按特殊人群管理,采用个体化给药方案。
  • 对低体重患者使用抗菌药和抗凝药时,可利用治疗药物监测或实验室监测参数调整剂量。
  • 对亲脂性药物不能简单套用亲水性药物的剂量结论。

局限性

  • 低体重患者剂量研究文献稀缺。
  • 现有证据主要限于抗菌药和抗凝药,外推受限。
  • 亲脂性药物及体重描述指标研究不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To highlight important considerations when designing dosing regimens for patients with low body weight. SUMMARY: Pharmacokinetic alterations that occur in patients with low body weight could lead to inappropriate drug concentrations and adverse effects if standard doses for patients with normal body habitus are used. In contrast to information on drug dosing in patients with obesity, there is a dearth of publications concerning drug dosing in patients with low body weight. Weight descriptors available for dosing patients with low body weight are the same as those used in obese patients but are not as well studied. However, there are general considerations regarding weight descriptors for weight-based drug dosing that are similar for patients with low or excess weight such as the lack of demonstrated usefulness of ideal body weight. The results of investigations that are available for drug dosing in patients with low body weight are primarily limited to antimicrobial and anticoagulant agents, which have well established forms of therapeutic drug monitoring or laboratory monitoring parameters. Of note, the antimicrobials and anticoagulants studied in patients with low body weight tend to be hydrophilic drugs that are eliminated by the kidneys. This has implications for pharmacokinetic parameters, including volume of distribution and clearance that may not be applicable for more lipophilic agents. There is little information on lipophilic drugs with larger volumes of distribution and often non-renal mechanisms of clearance. CONCLUSION: There is a paucity of information regarding drug dosing in patients with low body weight. The limited information suggests substantial variability in pharmacokinetic outcomes and clinical outcomes with standard doses in low weight patients. Nevertheless, this group should be considered a "special population" where individualized dosing approaches should be sought. More research is needed in this area particularly with respect to size descriptors useful for weight-based drug dosing and for lipophilic drugs that are not amenable to some form of therapeutic drug monitoring.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Erstad BL, Barletta JF. Drug dosing in patients with low body weight. Am J Health Syst Pharm. 2026. PMID: 42768985. doi:10.1093/ajhp/zxag292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。